Extended-release nifedipine and the risk of intestinal obstruction: a population-based study. Issue 7 (24th July 2014)

• Record Type: Journal Article
• Authors: Juurlink, David N; Hellings, Chelsea; Gomes, Tara; Huang, Anjie; Paterson, J Michael; Urbach, David R; Mamdani, Muhammad M
• Is Part Of: BMJ open. Volume 4:Issue 7(2014)
• Publication Date: 2014-07-24
• Subjects: GASTROENTEROLOGY; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2014-005377
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To examine the risk of bowel obstruction in older adults during treatment with extended-release nifedipine compared with patients treated with amlodipine. Design: Retrospective cohort study using multiple linked healthcare databases. Setting: Ontario, Canada from 1 April 1997 to 31 December 2010. Participants: We identified patients aged 66 years and older who started treatment with Adalat XL, an extended-release nifedipine product employing a tablet delivery system associated with mechanical bowel obstruction. For comparison, we studied patients receiving amlodipine, a long-acting calcium channel blocker that does not utilise the same delivery system and has not been implicated as a cause of bowel obstruction. Propensity score matching was used to ensure similarity of patients receiving the two drugs. Primary outcome measure: HR for the association between extended-release nifedipine relative to amlodipine and hospitalisation for bowel obstruction during therapy. Results: Over the 13-year study period, we identified 103 657 patients treated with extended-release nifedipine and 204 733 patients treated with amlodipine. In these two groups, 591 (0.6%) and 1185 (0.6%) of patients were hospitalised for bowel obstruction, respectively. We found no difference in the risk of bowel obstruction among patients treated with extended-release nifedipine compared with amlodipine (HR 1.09, 95% CI 0.96 to 1.24). Conclusions: Bowel obstruction during treatment with extended-release nidefipine is rare, and the risk is not appreciably greater than that during treatment with amlodipine.